BIGBEAR
PHARMACEUTICAL
Sotorasib covalently binds to the switch pocket of KRAS G12C mutant protein, specifically inhibits GTPase activity and blocks abnormal RAS signaling.
AuthenticGuaranteeFast DeliveryPrivacy For pregnant and lactating patients, if Sotorasib is to be used, it should be strictly in accordance with the doctor's advice, and do not use the ···【More】
Update: 03 Jul,2026Source: BigbearViews: 178
Sotorasib Daily PrecautionsWhat daily precautions should be taken during Sotorasib treatment? It is important to actively maintain contact with your d···【More】
Update: 03 Jul,2026Source: BigbearViews: 141
Mechanism of Action of SotorasibIrreversibly and selectively inhibits KRASG12C mutation, selectively inhibits KRAS signaling and cell growth in vitro,···【More】
Update: 03 Jul,2026Source: BigbearViews: 150
Sotorasib is the first approved KRAS G12C-targeted therapy, indicated for the treatment of non-small cell lung cancer and colorectal cancer with KRAS ···【More】
Update: 03 Jul,2026Source: BigbearViews: 127
Side Effects of SotorasibHematologicVery common (≥10%): lymphopenia (up to 48%), decreased hemoglobin (up to 43%), prolonged activated partial thrombo···【More】
Update: 03 Jul,2026Source: BigbearViews: 142
Use of Sotorasib may cause a range of side effects, some of which are serious and require prompt medical attention. During treatment with Sotorasib, c···【More】
Update: 02 Jul,2026Source: BigbearViews: 154
If adverse reactions occur, a maximum of 2 dose reductions are permitted: first dose reduction, 480 mg orally once daily; second dose reduction, 240 m···【More】
Update: 01 Jul,2026Source: BigbearViews: 170
Sotorasib is indicated for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at leas···【More】
Update: 30 Jun,2026Source: BigbearViews: 158
Sotorasib is an oral targeted cancer therapy drug that received U.S. FDA approval in May 2021 (marketed under the brand name Lumakras). It is indicate···【More】
Update: 27 Apr,2026Source: BigbearViews: 182
KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【More】
Update: 04 Mar,2026Source: BigbearViews: 163
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【More】
Update: 03 Mar,2026Source: BigbearViews: 176
In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【More】
Update: 03 Mar,2026Source: BigbearViews: 174
Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【More】
Update: 03 Mar,2026Source: BigbearViews: 176
Sotorasib is a targeted drug against KRASG12C mutations, primarily used to treat malignant tumors such as non-small cell lung cancer. Common side effe···【More】
Update: 27 Feb,2026Source: BigbearViews: 162
While taking sottorazib, it is generally not recommended to consume large amounts of fatty foods. However, small or occasional intake is usually harml···【More】
Update: 27 Feb,2026Source: BigbearViews: 157
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
